GB201300903D0 - Crystalline Form - Google Patents

Crystalline Form

Info

Publication number
GB201300903D0
GB201300903D0 GBGB1300903.0A GB201300903A GB201300903D0 GB 201300903 D0 GB201300903 D0 GB 201300903D0 GB 201300903 A GB201300903 A GB 201300903A GB 201300903 D0 GB201300903 D0 GB 201300903D0
Authority
GB
United Kingdom
Prior art keywords
crystalline form
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1300903.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canbex Therapeutics Ltd
Original Assignee
Canbex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canbex Therapeutics Ltd filed Critical Canbex Therapeutics Ltd
Priority to GBGB1300903.0A priority Critical patent/GB201300903D0/en
Publication of GB201300903D0 publication Critical patent/GB201300903D0/en
Priority to CN201480013204.7A priority patent/CN105142626A/zh
Priority to PCT/GB2014/050127 priority patent/WO2014111720A1/en
Priority to JP2015553165A priority patent/JP2016505036A/ja
Priority to US14/760,592 priority patent/US9682924B2/en
Priority to EP14702299.0A priority patent/EP2945619B1/en
Priority to RU2015134560A priority patent/RU2015134560A/ru
Priority to NZ630795A priority patent/NZ630795A/en
Priority to CA2897524A priority patent/CA2897524A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/69—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1300903.0A 2013-01-18 2013-01-18 Crystalline Form Ceased GB201300903D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1300903.0A GB201300903D0 (en) 2013-01-18 2013-01-18 Crystalline Form
CN201480013204.7A CN105142626A (zh) 2013-01-18 2014-01-17 Vsn16的结晶形态
PCT/GB2014/050127 WO2014111720A1 (en) 2013-01-18 2014-01-17 Crystalline form of vsn16
JP2015553165A JP2016505036A (ja) 2013-01-18 2014-01-17 Ｖｓｎ１６の結晶形態
US14/760,592 US9682924B2 (en) 2013-01-18 2014-01-17 Crystalline form of VSN16
EP14702299.0A EP2945619B1 (en) 2013-01-18 2014-01-17 Crystalline form of vsn16
RU2015134560A RU2015134560A (ru) 2013-01-18 2014-01-17 Кристаллическая форма vsn16
NZ630795A NZ630795A (en) 2013-01-18 2014-01-17 Crystalline form of vsn16
CA2897524A CA2897524A1 (en) 2013-01-18 2014-01-17 Crystalline form of vsn16

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1300903.0A GB201300903D0 (en) 2013-01-18 2013-01-18 Crystalline Form

Publications (1)

Publication Number Publication Date
GB201300903D0 true GB201300903D0 (en) 2013-03-06

Family

ID=47843537

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1300903.0A Ceased GB201300903D0 (en) 2013-01-18 2013-01-18 Crystalline Form

Country Status (9)

Country Link
US (1) US9682924B2 (https=)
EP (1) EP2945619B1 (https=)
JP (1) JP2016505036A (https=)
CN (1) CN105142626A (https=)
CA (1) CA2897524A1 (https=)
GB (1) GB201300903D0 (https=)
NZ (1) NZ630795A (https=)
RU (1) RU2015134560A (https=)
WO (1) WO2014111720A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3256112A1 (en) * 2015-02-13 2017-12-20 Canbex Therapeutics Limited Compounds for treating disorders associated with bk channel modulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0403864D0 (en) * 2004-02-20 2004-03-24 Ucl Ventures Modulator
GB0903956D0 (en) 2009-03-06 2009-04-22 Ucl Business Plc Process

Also Published As

Publication number Publication date
WO2014111720A1 (en) 2014-07-24
EP2945619B1 (en) 2019-05-08
RU2015134560A (ru) 2017-02-28
US20150353476A1 (en) 2015-12-10
US9682924B2 (en) 2017-06-20
CA2897524A1 (en) 2014-07-24
CN105142626A (zh) 2015-12-09
EP2945619A1 (en) 2015-11-25
JP2016505036A (ja) 2016-02-18
NZ630795A (en) 2016-07-29

Similar Documents

Publication Publication Date Title
IL249517A0 (en) A compound that inhibits trk
AP2015008713A0 (en) Tetrahydropyrrolothiazine compounds
GB201302927D0 (en) Compounds
GB201302368D0 (en) Compound
ZA201507044B (en) Pyridinylpyrazoloquinoline compound
IL240348A0 (en) Transmuted imidazopyridines
ZA201600275B (en) Substituted pyrazolo-pyridinamines
IL246271A0 (en) Converted piperidinyl-tetrahydroquinolines
AP3850A (en) Azetidinyloxyphenylpyrrolidine compounds
GB201414328D0 (en) None
IL242331B (en) Preparation of Amorphous Taquirimate
EP2948457A4 (en) COMPOUNDS
GB201417087D0 (en) No detials
GB201307331D0 (en) Compound
GB201300903D0 (en) Crystalline Form
GB201408643D0 (en) Compound
GB201410951D0 (en) None
GB201300647D0 (en) Crystallization
GB201410424D0 (en) None
GB201322438D0 (en) Compound
GB201315772D0 (en) Compound
GB201305634D0 (en) Compound
GB201304250D0 (en) Compound
GB201301585D0 (en) Compound
GB201303482D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)